Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 1998

View Archived Issues

Hemodynamic and electrophysiological effects of S-16257 assessed in dogs

EMD-96785: a promising cardioprotective agent from Merck KGaA

NHE inhibition with dietary cariporide proves beneficial in infarct model

Company Profile: Biosyn

Gensia Sicor and Asta Medica to develop new formulation of peptide

Collaboration extended for gonorrhea vaccine development

SR-146131, the most potent CCK-A receptor agonist reported to date

Sparta receives FDA approval for phase II/III trials of Spartaject busulfan

Avigen and Cell Genesys report success with gene therapy of hemophilia B

Reticulose stimulates immune system in HIV-infected patients

Cordox enters phase II for treatment of heart transplant patients

Venlafaxine: cause of cardiac toxicity identified

RU-58642: potent new antiandrogen for androgen-dependent prostate disorders

Cel-Sci receives SBIR grant for herpes simplex vaccine

Nibentan, a potentially safer class III antiarrhythmic agent

Advances in ChimeriVax vaccines presented by OraVax

New lipoxygenase inhibitors for asthma and other inflammatory conditions

Theratechnologies' GRF analogues receive patent coverage

CytoTherapeutics terminates collaboration with Genentech, redirects focus

Potent new cholesterol biosynthesis inhibitors reported by Novartis

Research demonstrates vital role of hMSCs in hematopoiesis

Long-term efficacy of AAV-based gene therapy for Parkinson's disease in animal models

GeneMedicine and University of Texas collaborate on genetic vaccines

Megamerger of AHP and Monsanto announced

Liarozole, a RAMBA with clinical efficacy in treating prostate cancer

FDA advisory committee recommends expanded use of Taxotere

Vinflunine, a vinca alkaloid with more potent activity than vinorelbine in preclinical models

Beth Israel researchers discover new enzyme that protects neurons from apoptosis

Comparative in vitro activity and other properties described for MEN-10700

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...